Sector of the day · Scheduled

Health & Biotech

Health & Biotech companies raised $20.9B in equity in 2025–2026, 3.1% of all tracked capital, and 2026 has already passed 2025 ($12.6B against $8.4B).

Open on the globeSector pageSocial slides

$20.9BEquity raised, 2025–20262025 $8.4B · 2026 $12.6B
1.5×2026 vs 20252026 to 15 Nov 2026
40Companies59 equity rounds in 2025–2026
$2.1BBiggest roundIsomorphic Labs, Series B

Top raisers equity in 2025–2026, log scale

Isomorphic Labs leads with $2.7B, 13% of the sector's equity in 2025–2026.

  1. Isomorphic LabsLondon$2.7B
  2. MiRusMarietta$1.5B
  3. Parabilis MedicinesCambridge$975M
  4. Neko HealthStockholm$960M
  5. OuraOulu$900M
  6. Earendil LabsWilmington$787M
  7. Eikon TherapeuticsMillbrae$732M
  8. OpenEvidenceCambridge$660M
  9. NeuralinkFremont$650M
  10. Pathos AINew York$602M

Biggest rounds log scale

The biggest single round was Isomorphic Labs' $2.1B Series B on 12 May 2026, led by Thrive Capital.

Where the money went by stage equity in 2025–2026

Series C to E rounds took 34% of the equity; the median round there was $287M.

  1. Seed to Series B16 rounds, median $257M$5.9B
  2. Series C to E25 rounds, median $287M$7.2B
  3. Series F and later6 rounds, median $290M$2.1B
  4. Strategic and unlabelled12 rounds, median $335M$5.8B

Most active investors companies backed in 2025–2026

T. Rowe Price backed 8 Health companies in 2025–2026. For RA Capital Management the sector is 100% of its tracked portfolio.

  1. T. Rowe Price22% of portfolio8 companies
  2. ARCH Venture Partnersled 3 rounds · 86% of portfolio6 companies
  3. GVled 3 rounds · 29% of portfolio6 companies
  4. Fidelityled 2 rounds · 20% of portfolio6 companies
  5. General Catalystled 2 rounds · 15% of portfolio6 companies
  6. Thrive Capitalled 3 rounds · 36% of portfolio5 companies
  7. RA Capital Managementled 1 round · 100% of portfolio5 companies
  8. Blackstoneled 1 round · 25% of portfolio4 companies
  9. Janus Henderson Investorsled 1 round · 67% of portfolio4 companies
  10. Sequoia Capitalled 1 round · 9% of portfolio4 companies

Investor groups that repeat here all sourced rounds in the sector

ARCH Venture Partners and T. Rowe Price invested together in 5 Health rounds, across Kardigan, Mirador Therapeutics, Ollin Biosciences and 1 other.

  1. ARCH Venture PartnersT. Rowe Price5 rounds togetherKardigan, Mirador Therapeutics, Ollin Biosciences, Parabilis Medicines
  2. FidelityT. Rowe Price5 rounds togetherAdvanCell, Kardigan, Mirador Therapeutics, Parabilis Medicines
  3. Kleiner PerkinsThrive Capital5 rounds togetherChai Discovery, NewLimit, OpenEvidence
  4. Sequoia CapitalThrive Capital5 rounds togetherChai Discovery, Neuralink, OpenEvidence
  5. GVThrive Capital5 rounds togetherIsomorphic Labs, OpenEvidence

Where it happens equity in 2025–2026 by city

London is home to 2 of the 40 companies and 15% of the equity.

  1. London, GB2 companies$3.1B
  2. South San Francisco, US4 companies$1.7B
  3. Cambridge, US2 companies$1.6B
  4. Marietta, US1 company$1.5B
  5. New York, US3 companies$1.1B
  6. Stockholm, SE1 company$960M

Notes and sources

  • Totals count primary equity only. Health & Biotech ranks #8 of 12 sectors by equity raised in 2025–2026.
  • 2026 runs to 15 Nov 2026, so the year comparison is not like for like.
  • Investor groups: two or more shared rounds across two or more companies in the sector, over every sourced round.
  • Data as of 15 Nov 2026. See the methodology.